Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAO Regimen in Newly Diagnosed Ph-positive ALL
NCT06578546Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Feb 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax, azacitidine and olverembatinib in acute lymphoblastic leukemia (ALL), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Complete Molecular Remission. Started Feb 2024; status: recruiting.
02
Drugs
venetoclaxazacitidineolverembatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06578546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06578546.